← Leaderboards
Russell J Mumper
University Of Kentucky
$6,017,636
Attributed
$6,017,636
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–14$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$6,017,636 · 6
By mechanism
R01$2,490,066 · 2
U54$1,592,205 · 1
U19$1,222,011 · 1
R21$713,354 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Ligands”
- John Damon Chodera · Sloan-Kettering Inst Can Research$39,009,297
- Keith W Miller · Massachusetts General Hospital$35,506,092
- Ian A Wilson · Scripps Research Institute, The$35,392,112
- Bryan L Roth · Univ Of North Carolina Chapel Hill$32,442,555
- Edward Franklin Plow · Cleveland Clinic Foundation$32,215,714
- Helen M Berman · Rutgers University New Brunswick$32,076,400
Research focus
LigandsUniversitiesCellsIn VivoUptakeDoseOilsNanotechnologyEngineeringNanoparticleDrug Delivery SystemsToxic EffectBaseProgramsKentuckyMulti-Drug ResistanceNanosystemsImmunogenicityEpidermal Growth Factor ReceptorLaboratoriesDrug KineticsCancer PatientCancer TherapyCytotoxicity
Grant awards (25)
Translational Nanosystems for Improved Lung Cancer Treatment with Small Molecules$312,891
U54 · FY2014 · CA · contact PI
Translational Nanosystems for Improved Lung Cancer Treatment with Small Molecules$301,617
U54 · FY2013 · CA · contact PI
Translational Nanosystems for Improved Lung Cancer Treatment with Small Molecules$322,575
U54 · FY2012 · CA · contact PI
Translational Nanosystems for Improved Lung Cancer Treatment with Small Molecules$322,572
U54 · FY2011 · CA · contact PI
Translational Nanosystems for Improved Lung Cancer Treatment with Small Molecules$332,550
U54 · FY2010 · CA · contact PI
Nanoparticle HIV Protein Vaccines for Cellular Responses$279,795
R01 · FY2009 · AI · contact PI
EGFR Targeted Nanoparticles to Overcome Paclitaxel Resistant Breast Cancer$238,288
R01 · FY2009 · CA · contact PI
Nanoparticle HIV Protein Vaccines for Cellular Responses$279,144
R01 · FY2008 · AI · contact PI
EGFR Targeted Nanoparticles to Overcome Paclitaxel Resistant Breast Cancer$235,901
R01 · FY2008 · CA · contact PI
Core--Formulation Science$201,478
U19 · FY2008 · AI · contact PI
Core--Formulation Science$502,324
U19 · FY2007 · AI · contact PI
EGFR Targeted Nanoparticles to Overcome Paclitaxel Resistant Breast Cancer$220,307
R01 · FY2007 · CA · contact PI
Nanoparticle HIV Protein Vaccines for Cellular Responses$166,457
R01 · FY2007 · AI · contact PI
Nanoparticle HIV Protein Vaccines for Cellular Responses$161,365
R01 · FY2007 · AI · contact PI
EGFR Targeted Nanoparticles to Overcome Paclitaxel Resistant Breast Cancer$29,003
R01 · FY2007 · CA · contact PI
Nanoparticle HIV Protein Vaccines for Cellular Responses$321,495
R01 · FY2006 · AI · contact PI
EGFR Targeted Nanoparticles to Overcome Paclitaxel Resistant Breast Cancer$271,756
R01 · FY2006 · CA · contact PI
Core--Formulation Science$161,953
U19 · FY2006 · AI · contact PI
Nanoparticle HIV Protein Vaccines for Cellular Responses$286,555
R01 · FY2005 · AI
Core--Formulation Science$171,593
U19 · FY2005 · AI
Nanoengineered HIV-1 Vaccines Based on Tat$200,338
R21 · FY2004 · AI
Core--Formulation Science$184,663
U19 · FY2004 · AI
Nanoengineered HIV-1 Vaccines Based on Tat$212,152
R21 · FY2003 · AI
NANOTEMPLATE ENGINEERING OF CELL-SPECIFIC NANOPARTICLES$146,855
R21 · FY2003 · EB
NANOTEMPLATE ENGINEERING OF CELL-SPECIFIC NANOPARTICLES$154,009
R21 · FY2002 · EB